
    
      OBJECTIVES:

      Primary

        -  Characterize the safety profile of Ad-sig-hMUC-1/ecdCD40L vaccine in women with
           metastatic breast cancer.

        -  Identify a tolerable, immunologically active dose level of this vaccine in these
           patients.

      Secondary

        -  Evaluate the immune function in these patients before and after treatment with this
           vaccine.

      OUTLINE: Patients receive MUC-1 vector vaccine subcutaneously on day 0.

      After completion of study treatment, patients are followed monthly for 9 months.
    
  